Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings
{{output}}
Background: ALK-positive lung cancers are known to have favorable responses with oral tyrosine kinase inhibitors. Lorlatinib is an approved treatment option post first and second-line ALK inhibitors and is now also in first line.... ...
